clinical trials

Recent Rosacea Blog Posts

Rossoseq for the Redness of Rosacea

A new product known as Rossoseq is to be trialled as a treatment for the redness of rosacea. The trial is sponsored by a company calling itself PBB Entrepreneur Ltd. and seems to be based in Germany. 60 people are to be enrolled in the trial, which is due to be completed by October 2012. […]

Continue Reading

Comparing Sansrosa to Finacea for Redness

Galderma are surely confirming that the development of Sansrosa 0.5% Gel (CD07805/47) is nearing completion, with the posting of a proposed comparison trial with Finacea. The trial NCT01659853 will compare how effective Sansrosa is compared to Finacea. The primary outcome will be to assess, after 15 days, an improvement in facial redness. The secondary outcome […]

Continue Reading

T4O Pads (Terpinen-4-ol) for Ocular Demodex

An interesting new product that contains the main active ingredient from Tea Tree Oil has emerged in a new clinical trial listing. The trial titled Demodex Blepharitis Treatment Study, is sponsored by a company called Tissue Tech Inc. of Florida (who don’t seem to have a web site). Trial NCT01647217 seeks to prove that terpinen-4-ol […]

Continue Reading

Aczone Fails to Impress for Rosacea

We don’t often get to see the actual results from clinical trials. Companies are happy to receive publicity for their research and development programs, especially if a new product looks promising. If things don’t go we during clinical trials, though, it seems that we just never hear about that product again. Allergan, the makes of […]

Continue Reading

Intendis, the makers of Finacea are to trial the combination of ND:Yag laser treatment with and without the addition of Finacea during treatment. As the study will be a spilt face trial, researchers will be able to show that the addition of Finacea does, or does not make a difference to the outcome of the […]

Continue Reading



Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.